Last week, Immunomic founder and CEO Dr. Bill Hearl presented at the BIO Investor Forum in San Francisco, California.
Following a company overview, Dr. Hearl discussed Immunomic’s recently-expanded investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology, specifically glioblastoma multiforme (GBM), a deadly form of brain cancer.
You can access the webcast of Dr. Hearl’s presentation here.
Immunomic’s technology platform has the potential to utilize the body’s natural biochemistry to develop a broad immune response and is currently being employed in a Phase II clinical trial as a cancer immunotherapy.
For more information about Immunomic’s technology visit https://www.immunomix.com/unite/.